ASTRAZENECA PLC (ZEG.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:ZEG - GB0009895292 - Common Stock
154.75 EUR
-1 (-0.64%)
Taking everything into account, ZEG scores 5 out of 10 in our fundamental rating. ZEG was compared to 54 industry peers in the Pharmaceuticals industry. While ZEG belongs to the best of the industry regarding profitability, there are concerns on its financial health. ZEG is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ZEG had positive earnings in the past year.
ZEG had a positive operating cash flow in the past year.
ZEG had positive earnings in each of the past 5 years.
Each year in the past 5 years ZEG had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 8.21%, ZEG is in the better half of the industry, outperforming 64.81% of the companies in the same industry.
ZEG has a Return On Equity of 20.48%. This is in the better half of the industry: ZEG outperforms 68.52% of its industry peers.
With a decent Return On Invested Capital value of 14.42%, ZEG is doing good in the industry, outperforming 72.22% of the companies in the same industry.
ZEG had an Average Return On Invested Capital over the past 3 years of 11.62%. This is below the industry average of 13.89%.
The 3 year average ROIC (11.62%) for ZEG is below the current ROIC(14.42%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROIC | 14.42% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
The Profit Margin of ZEG (16.17%) is better than 64.81% of its industry peers.
In the last couple of years the Profit Margin of ZEG has grown nicely.
ZEG has a Operating Margin of 24.34%. This is in the better half of the industry: ZEG outperforms 62.96% of its industry peers.
ZEG's Operating Margin has improved in the last couple of years.
ZEG has a Gross Margin of 81.90%. This is amongst the best in the industry. ZEG outperforms 83.33% of its industry peers.
In the last couple of years the Gross Margin of ZEG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
ZEG has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
ZEG has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, ZEG has more shares outstanding
Compared to 1 year ago, ZEG has a worse debt to assets ratio.
2.2 Solvency
ZEG has an Altman-Z score of 5.89. This indicates that ZEG is financially healthy and has little risk of bankruptcy at the moment.
ZEG's Altman-Z score of 5.89 is amongst the best of the industry. ZEG outperforms 81.48% of its industry peers.
The Debt to FCF ratio of ZEG is 3.41, which is a good value as it means it would take ZEG, 3.41 years of fcf income to pay off all of its debts.
ZEG has a Debt to FCF ratio of 3.41. This is comparable to the rest of the industry: ZEG outperforms 57.41% of its industry peers.
A Debt/Equity ratio of 0.61 indicates that ZEG is somewhat dependend on debt financing.
The Debt to Equity ratio of ZEG (0.61) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Altman-Z | 5.89 |
ROIC/WACC1.6
WACC9%
2.3 Liquidity
A Current Ratio of 0.88 indicates that ZEG may have some problems paying its short term obligations.
With a Current ratio value of 0.88, ZEG is not doing good in the industry: 81.48% of the companies in the same industry are doing better.
A Quick Ratio of 0.69 indicates that ZEG may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.69, ZEG is doing worse than 77.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
ZEG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.61%, which is quite impressive.
Measured over the past years, ZEG shows a quite strong growth in Earnings Per Share. The EPS has been growing by 18.59% on average per year.
The Revenue has grown by 13.52% in the past year. This is quite good.
ZEG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.27% yearly.
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
3.2 Future
ZEG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.45% yearly.
The Revenue is expected to grow by 7.17% on average over the next years.
EPS Next Y14.12%
EPS Next 2Y13.77%
EPS Next 3Y13.01%
EPS Next 5Y12.45%
Revenue Next Year10.13%
Revenue Next 2Y8.09%
Revenue Next 3Y7.31%
Revenue Next 5Y7.17%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 19.76, the valuation of ZEG can be described as rather expensive.
The rest of the industry has a similar Price/Earnings ratio as ZEG.
ZEG is valuated rather cheaply when we compare the Price/Earnings ratio to 26.34, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 16.97, the valuation of ZEG can be described as correct.
ZEG's Price/Forward Earnings is on the same level as the industry average.
ZEG is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.56, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.76 | ||
| Fwd PE | 16.97 |
4.2 Price Multiples
ZEG's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. ZEG is more expensive than 68.52% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ZEG indicates a slightly more expensive valuation: ZEG is more expensive than 66.67% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 58.45 | ||
| EV/EBITDA | 28.1 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of ZEG may justify a higher PE ratio.
ZEG's earnings are expected to grow with 13.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.4
PEG (5Y)1.06
EPS Next 2Y13.77%
EPS Next 3Y13.01%
5. Dividend
5.1 Amount
ZEG has a Yearly Dividend Yield of 1.81%. Purely for dividend investing, there may be better candidates out there.
ZEG's Dividend Yield is comparable with the industry average which is at 2.90.
ZEG's Dividend Yield is slightly below the S&P500 average, which is at 2.31.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.81% |
5.2 History
The dividend of ZEG has a limited annual growth rate of 1.40%.
Dividend Growth(5Y)1.4%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
52.89% of the earnings are spent on dividend by ZEG. This is a bit on the high side, but may be sustainable.
The dividend of ZEG is growing, but earnings are growing more, so the dividend growth is sustainable.
DP52.89%
EPS Next 2Y13.77%
EPS Next 3Y13.01%
FRA:ZEG (12/8/2025, 7:00:00 PM)
154.75
-1 (-0.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners48.98%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap479.81B
Revenue(TTM)58.13B
Net Income(TTM)9.40B
Analysts82.42
Price Target165.09 (6.68%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.81% |
Yearly Dividend2.56
Dividend Growth(5Y)1.4%
DP52.89%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-1.74%
Max EPS beat(2)1.47%
EPS beat(4)2
Avg EPS beat(4)2.1%
Min EPS beat(4)-1.74%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)0.88%
EPS beat(12)8
Avg EPS beat(12)2.53%
EPS beat(16)12
Avg EPS beat(16)3.75%
Revenue beat(2)0
Avg Revenue beat(2)-0.25%
Min Revenue beat(2)-0.26%
Max Revenue beat(2)-0.24%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)3
Avg Revenue beat(8)0.07%
Revenue beat(12)4
Avg Revenue beat(12)-0.52%
Revenue beat(16)6
Avg Revenue beat(16)0.18%
PT rev (1m)5.27%
PT rev (3m)5.12%
EPS NQ rev (1m)-1.7%
EPS NQ rev (3m)-3.47%
EPS NY rev (1m)0.29%
EPS NY rev (3m)0.38%
Revenue NQ rev (1m)0.03%
Revenue NQ rev (3m)-0.25%
Revenue NY rev (1m)0.5%
Revenue NY rev (3m)0.69%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.76 | ||
| Fwd PE | 16.97 | ||
| P/S | 9.62 | ||
| P/FCF | 58.45 | ||
| P/OCF | 36.94 | ||
| P/B | 12.19 | ||
| P/tB | N/A | ||
| EV/EBITDA | 28.1 |
EPS(TTM)7.83
EY5.06%
EPS(NY)9.12
Fwd EY5.89%
FCF(TTM)2.65
FCFY1.71%
OCF(TTM)4.19
OCFY2.71%
SpS16.09
BVpS12.7
TBVpS-3.74
PEG (NY)1.4
PEG (5Y)1.06
Graham Number47.3
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROCE | 17.6% | ||
| ROIC | 14.42% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 81.56% | ||
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% | ||
| FCFM | 16.46% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexgc growth 3Y43.28%
ROICexgc growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Debt/EBITDA | 1.34 | ||
| Cap/Depr | 84.97% | ||
| Cap/Sales | 9.59% | ||
| Interest Coverage | 10.83 | ||
| Cash Conversion | 73.11% | ||
| Profit Quality | 101.79% | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z | 5.89 |
F-Score7
WACC9%
ROIC/WACC1.6
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
EPS Next Y14.12%
EPS Next 2Y13.77%
EPS Next 3Y13.01%
EPS Next 5Y12.45%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
Revenue Next Year10.13%
Revenue Next 2Y8.09%
Revenue Next 3Y7.31%
Revenue Next 5Y7.17%
EBIT growth 1Y26.07%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year34.11%
EBIT Next 3Y17.46%
EBIT Next 5Y13.16%
FCF growth 1Y37.12%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y46.1%
OCF growth 3Y25.76%
OCF growth 5Y31.92%
ASTRAZENECA PLC / ZEG.DE FAQ
What is the fundamental rating for ZEG stock?
ChartMill assigns a fundamental rating of 5 / 10 to ZEG.DE.
What is the valuation status for ZEG stock?
ChartMill assigns a valuation rating of 3 / 10 to ASTRAZENECA PLC (ZEG.DE). This can be considered as Overvalued.
What is the profitability of ZEG stock?
ASTRAZENECA PLC (ZEG.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for ZEG stock?
The Price/Earnings (PE) ratio for ASTRAZENECA PLC (ZEG.DE) is 19.76 and the Price/Book (PB) ratio is 12.19.
Can you provide the financial health for ZEG stock?
The financial health rating of ASTRAZENECA PLC (ZEG.DE) is 3 / 10.